Malin Pedersen

11PUBLICATIONS
50CO-AUTHORS
Biologically active moleculesCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Oct 15, 2026
Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes anti-tumour immunity in combination with radiotherapy.

|Oct 12, 2026
Addition of chemotherapy to radiotherapy promotes progenitor-exhausted CD8⁺ T-cell clonal dominance in head and neck cancer.

|Apr 27, 2026
Tissue-specific fibroblast lipid cues impose the rate of epithelial cancer invasion.

|Mar 03, 2026
Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling.

Victoria Roulstone, Joan Kyula, Elizabeth Appleton

|Oct 22, 2025
Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer.

Charleen Chan Wah Hak, Emmanuel C Patin, Anton Patrikeev

|Sep 26, 2025
Addition of oncolytic virotherapy to clinical isolated limb perfusion for melanoma and sarcoma activates antitumor immunity.

Andrew J Hayes, Emma J Davies, Michelle Wilkinson

Pageof 2

Frequent Collaborators

8 joint publications

Emmanuel Patin

8 joint publications

Kevin J Harrington

7 joint publications

Alan Melcher

4 joint publications

Charleen Ml Chan Wah Hak